4Iyer RV, Haynes PT, Schneider RF, et al. Marking hypoxia in rat prostate carcinomas with beta-D-[125I] azomycin galactopyranoside and [Tc-99m] HL-91: Correlation with microelectrode measure- merits. J Nucl Med, 2001, 42(2): 337-344.
5Siim BG, Laux WT, Rutland MD, et al .Scintigraphic imaging of the hypoxia marker (99re)technetium-labeled 2, 2 "-(1, 4-diaminobu- tane)bis(2-methyl-3-butanone)dioxime (m Tc-labeled HL-91; Prog- nox): noninvasive detection of tumor response to the antivas-cular agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Res, 2000, 60 (16): 4582-4588.
6Zhang X, Melo T, Ballinger JR, et al . Studies of 99mTc-BnAO (HL- 91): a non-nitroaromatic compound for hypoxic cell detection.Int J Radiat Oncol Biol Phys, 1998, 42 (4) : 737-740.
7Yutani K, Kusuoka H, Fukuchi K, et al. Applicability of99mTc- HLgl, a putative hypoxic tracer, to detection of tumor hypoxia. J Nucl Med, 1999, 40( 5 ): 854-861.
8Ballinger JR. hnaging hypoxia in tumors. Semin Nucl Med, 2001, 31(4): 321-329.
9Vaupel P, Kallinowski F, Okunieff P. Blood flow,oxygen and nutri- ent supply and metabolic mieroenvironment of human tumors. Cancer Res, 1989, 49(23): 6449-6465.
10Okada, RD, Johnson, G , Nguyen, KN , et al. HL-91-technetium- 99m: a new marker of viability in ischemic myocardium. J Nucl Cardiol, 1999, 6(3): 306-315.
